Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis

Kidney International

Volumn 86, Issue 2, 2014, Pages 370-377

  Said, Samar M ^a   Sethi, Sanjeev ^a   Valeri, Anthony M ^b   Chang, Anthony ^c   Nast, Cynthia C ^d   Krahl, Leslie ^e   Molloy, Peter ^e   Barry, Marc ^f   Fidler, Mary E ^a   Cornell, Lynn D ^a   Leung, Nelson ^a   Vrana, Julie A ^a   Theis, Jason D ^a   Dogan, Ahmet ^a   Nasr, Samih H ^a  

^a MAYO CLINIC   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

mass spectrometry; nephrology; proteinuria; renal biopsy; transplant outcomes

Indexed keywords

CREATININE; IMMUNOGLOBULIN LIGHT CHAIN; LECT2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULOSCLEROSIS; HEMATURIA; HISPANIC; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RARE DISEASE; RECURRENT DISEASE; RENAL AMYLOIDOSIS DERIVED FROM LEUKOCYTE CHEMOTACTIC FACTOR 2; SURVIVAL TIME; URINE SEDIMENT; AMYLOIDOSIS; DISEASE COURSE; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84905501130     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.558     Document Type: Article

References (25)

1. Benson MD, James S, Scott K et al. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int 2008; 74: 218-222.
2. Larsen CP, Walker PD, Weiss DT et al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 2010; 77: 816-819.
3. Said SM, Sethi S, Valeri AM et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013; 8: 1515-1523.
4. Murphy CL, Wang S, Kestler D et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 2010; 56: 1100-1107.
5. Murphy C, Wang S, Kestler D et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis. Amyloid 2011; 18(Suppl 1): 223-225.
6. Verine J, Mourad N, Desseaux K et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007; 38: 1798-1809.
7. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-1268.
8. McBean AM, Li S, Gilbertson DT et al. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, hispanics, and asians. Diabetes Care 2004; 27: 2317-2324.
9. Dogan ATJ, Vrana JA et al. Clinical and pathological phenotype of leukocyte cell-derived chemo- taxin-2 (LECT2) amyloidosis (ALECT2) (abstract OP-058). Amyloid 2010; 17(Suppl 1): 69-70.
10. Bergesio F, Ciciani AM, Manganaro M et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008; 23: 941-951.
11. Nasr SH, Said SM, Valeri AM et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013; 83: 463-470.
12. Gertz MA, Leung N, Lacy MQ et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009; 24: 3132-3137.
13. Picken MM. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis. Contrib Nephrol 2007; 153: 135-155.
14. Gillmore JD, Lachmann HJ, Rowczenio D et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009; 20: 444-451.
15. Gregorini G, Izzi C, Obici L et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005; 16: 3680-3686.
16. Sethi S, Theis JD, Shiller SM et al. Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 2012; 81: 201-206.
17. Sethi S, Vrana JA, Theis JD et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82: 226-234.
18. Yamagoe S, Yamakawa Y, Matsuo Y et al. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 1996; 52: 9-13.
19. Okumura A, Saito T, Otani I et al. Suppressive role of leukocyte cellderived chemotaxin 2 in mouse anti-type II collagen antibody-induced arthritis. Arthritis Rheum 2008; 58: 413-421.
20. Lu XJ, Chen J, Yu CH et al. LECT2 protects mice against bacterial sepsis by activating macrophages via the CD209a receptor. J Exp Med 2013; 210: 5-13.
21. Yamagoe S, Akasaka T, Uchida T et al. Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immunochemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. Biochem Biophys Res Commun 1997; 237: 116-120.
22. Nagai H, Hamada T, Uchida T et al. Systemic expression of a newly recognized protein, LECT2, in the human body. Pathol Int 1998; 48: 882-886.
23. Benson MD. LECT2 amyloidosis. Kidney Int 2010; 77: 757-759.
24. Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-4959.
25. Holanda DG, Acharya VK, Dogan A et al. Atypical presentation of atypical amyloid. Nephrol Dial Transplant 2011; 26: 373-376.